AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31022555 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 241
Study 27830950 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall of partner successfully resisting a cigarette
Number of subjects: 131
Study 27830950 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall of partner failing to resist a cigarette
Number of subjects: 131
Study 27830950 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no recall)
Number of subjects: 131
Study 26498386 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 125, 250, and 500 μg
Number of subjects: 4873
Study 26498386 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 500 μg with 400 μg BDP
Number of subjects: 4873
Study 26498386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4873
Study 23356382 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring intervention
Number of subjects: 133
Study 20383545 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% casein phosphopeptide‐amorphous calcium phosphate (CPP‐ACP) applied once daily (Tooth Mousse, GC Europe)
Number of subjects: 60
Study 20383545 — intervention group
Group type: COMPARATOR
Intervention: Standard fluoride toothpaste (control group)
Number of subjects: 60
Study 19468787 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxyphylline (800 mg daily) and vitamin E (800 UI daily)
Number of subjects: 12
Study 19468787 — intervention group
Group type: COMPARATOR
Intervention: Historical control group treated with cyclophosphamide for 6 months
Number of subjects: 12
Study 17315221 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch procedure
Number of subjects: 655
Study 17315221 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fascia sling procedure
Number of subjects: 655
Study 15841813 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting whole salivary secretion rate < or =0.1 mL/min
Number of subjects: 30
Study 15841813 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulated whole salivary flow rates <0.7 mL/min
Number of subjects: 30
Study 15841813 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary tests taken on several occasions
Number of subjects: 30
Study 11045792 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen and N-[4-hydroxyphenyl] retinamide
Number of subjects: 100
Study 11045792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 8956556 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive variceal pressure measurement with the endoscopic gauge
Number of subjects: 0
Study 8956556 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment of variceal bleeding
Number of subjects: 0
Study 15374404 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucin-containing artificial saliva
Number of subjects: 85
Study 15374404 — intervention group
Group type: COMPARATOR
Intervention: Placebo liquid
Number of subjects: 85
Study 2581467 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 100 mg orally once a day for 4 weeks
Number of subjects: 20
Study 2581467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30958069 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 µg of formoterol (FOR)
Number of subjects: 38
Study 30958069 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 µg of salmeterol (SAL)
Number of subjects: 38
Study 30958069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 30139419 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral caffeine supplementation (400 mg per dancer, 6.3 mg/kg, range: 4.9 to 8.6 mg/kg)
Number of subjects: 9
Study 30139419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 26747792 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive medical management
Number of subjects: 227
Study 24434055 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical yoga in addition to standard care for 12 weeks
Number of subjects: 6
Study 22834978 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth (TH) and telecare (TC) interventions
Number of subjects: 22
Study 22834978 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative semi-structured interviews
Number of subjects: 22
Study 19056575 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (1 mg . kg(‐1) . d(‐1)) from 4 to 9 months
Number of subjects: 25
Study 19056575 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (1 mg . kg(‐1) . d(‐1)) from 6 to 9 months
Number of subjects: 25
Study 19056575 — intervention group
Group type: COMPARATOR
Intervention: Placebo only
Number of subjects: 25
Study 17634458 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol 400 mg subcutaneously at weeks 0, 2, and 4, then every 4 weeks
Number of subjects: 662
Study 17634458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 662
Study 17634458 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Number of subjects: 662
Study 15588746 — intervention group
Group type: EXPERIMENTAL
Intervention: Industry-funded studies
Number of subjects: 0
Study 15588746 — intervention group
Group type: COMPARATOR
Intervention: Non-industry-funded studies
Number of subjects: 0
Study 15588746 — intervention group
Group type: EXPERIMENTAL
Intervention: Industry-funded studies with first authors employed by industry
Number of subjects: 0
Study 12847475 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg bid)
Number of subjects: 80
Study 12847475 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (250 microg bid)
Number of subjects: 80
Study 12847475 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (5 mg qid)
Number of subjects: 80
Study 12847475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 10597739 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated weekly schedule (AWS) of cisplatin (100 mg/m2 every week for two triplets of three cycles separated by a 5-week interval)
Number of subjects: 101
Study 10597739 — intervention group
Group type: COMPARATOR
Intervention: Conventional 3-weekly schedule (CTWS) of cisplatin (100 mg/m2 every 3 weeks for six cycles)
Number of subjects: 101
Study 8909705 — intervention group
Group type: EXPERIMENTAL
Intervention: SpaceLabs Medical oscillometric blood pressure monitor (neonatal study)
Number of subjects: 127
Study 8909705 — intervention group
Group type: EXPERIMENTAL
Intervention: SpaceLabs Medical oscillometric blood pressure monitor (adult study)
Number of subjects: 127
Study 1742390 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational newsletter
Number of subjects: 344
Study 1742390 — intervention group
Group type: COMPARATOR
Intervention: No informational newsletter
Number of subjects: 344
Study 6355242 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg per day
Number of subjects: 20
Study 6355242 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 240 mg per day
Number of subjects: 20
Study 6355242 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 360 mg per day
Number of subjects: 20
Study 6355242 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose diltiazem
Number of subjects: 20
Study 3919619 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG)
Number of subjects: 15
Study 3919619 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 15
Study 30151229 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (+50 g protein per day)
Number of subjects: 14
Study 30151229 — intervention group
Group type: COMPARATOR
Intervention: Normal-protein diet
Number of subjects: 14
Study 26026858 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician guided feedback
Number of subjects: 22
Study 26026858 — intervention group
Group type: COMPARATOR
Intervention: Tibial accelerometry
Number of subjects: 22
Study 24119101 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatic urethral lift (PUL)
Number of subjects: 0
Study 24119101 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 0
Study 24331630 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced nutritional therapy (n = 25)
Number of subjects: 50
Study 24331630 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 25)
Number of subjects: 50
Study 19350378 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention (MLH-I)
Number of subjects: 150
Study 19350378 — intervention group
Group type: EXPERIMENTAL
Intervention: Awaiting psychosocial intervention (MLH-W)
Number of subjects: 150
Study 19350378 — intervention group
Group type: COMPARATOR
Intervention: Control group (mothers without HIV)
Number of subjects: 150
Study 19350378 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite biomarker index (CBI)
Number of subjects: 150
Study 18768040 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (group A)
Number of subjects: 26
Study 18768040 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group P)
Number of subjects: 26
Study 16896724 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate
Number of subjects: 25
Study 16896724 — intervention group
Group type: EXPERIMENTAL
Intervention: 19‐norandrostenedione
Number of subjects: 25
Study 16896724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 14557756 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720 (0.125, 0.25, 0.5, 1.0, 2.5, or 5.0 mg/day)
Number of subjects: 76
Study 14557756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 14557756 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720
Number of subjects: 76
Study 10979067 — intervention group
Group type: EXPERIMENTAL
Intervention: No cleansing, urinate into a clean container (n = 77)
Number of subjects: 242
Study 10979067 — intervention group
Group type: EXPERIMENTAL
Intervention: Midstream urine sample with perineal cleansing (n = 84)
Number of subjects: 242
Study 10979067 — intervention group
Group type: EXPERIMENTAL
Intervention: Midstream urine sample with perineal cleansing and vaginal tampon (n = 81)
Number of subjects: 242
Study 10979067 — intervention group
Group type: COMPARATOR
Intervention: Combined cleansing, midstream groups
Number of subjects: 242
Study 8774628 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant regimen (vitamins E, C and N‐acetylcysteine)
Number of subjects: 25
Study 8774628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 8774628 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant regimen (vitamins E, C and N‐acetylcysteine) in chemotherapy group
Number of subjects: 25
Study 8774628 — intervention group
Group type: COMPARATOR
Intervention: Placebo in chemotherapy group
Number of subjects: 25
Study 8774628 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant regimen (vitamins E, C and N‐acetylcysteine) in radiotherapy group
Number of subjects: 25
Study 8774628 — intervention group
Group type: COMPARATOR
Intervention: Placebo in radiotherapy group
Number of subjects: 25
Study 1377359 — intervention group
Group type: EXPERIMENTAL
Intervention: Moricizine
Number of subjects: 1325
Study 1377359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1325
Study 31168845 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoids plus piperine (500 mg curcuminoids and 5 mg piperine daily)
Number of subjects: 70
Study 31168845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 29521740 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral therapy
Number of subjects: 200
Study 29521740 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antiviral therapy)
Number of subjects: 200
Study 26842679 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 2827
Study 26842679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2827
Study 24519908 — intervention group
Group type: EXPERIMENTAL
Intervention: Early physical activity (PA) measured by implanted devices, averaged over the earliest 30-day study period.
Number of subjects: 781
Study 24519908 — intervention group
Group type: EXPERIMENTAL
Intervention: Early physical activity (PA) measured by implanted devices.
Number of subjects: 781
Study 22564713 — intervention group
Group type: EXPERIMENTAL
Intervention: LTC (lonafarnib + carboplatin + paclitaxel)
Number of subjects: 105
Study 22564713 — intervention group
Group type: COMPARATOR
Intervention: TC (carboplatin + paclitaxel)
Number of subjects: 105
Study 19851772 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0
Study 19851772 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 0
Study 17914203 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsular tension ring (CTR) implantation
Number of subjects: 0
Study 17914203 — intervention group
Group type: COMPARATOR
Intervention: No intervention (without CTR)
Number of subjects: 0
Study 15685236 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive followup
Number of subjects: 6
Study 12134226 — intervention group
Group type: EXPERIMENTAL
Intervention: anti‐HCV regimen (interferon‐alpha2a and ribavirin)
Number of subjects: 36
Study 9708400 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir (NFV)
Number of subjects: 29
Study 9708400 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir (SQV)
Number of subjects: 29
Study 7893033 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (70%)
Number of subjects: 38
Study 7893033 — intervention group
Group type: COMPARATOR
Intervention: Control (no nitrous oxide)
Number of subjects: 38
Study 2527729 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven low-dose oral contraceptive preparations (monophasic and triphasic levonorgestrel, monophasic and biphasic desogestrel, monophasic norethisterone, monophasic cyproterone acetate, triphasic gestodene)
Number of subjects: 55
Study 2527729 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven low-dose oral contraceptive preparations
Number of subjects: 55
Study 326635 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics effective against obligate anaerobes
Number of subjects: 0
Study 326635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31587982 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Dexamethasone (DEX) 0.15 mg/kg
Number of subjects: 100
Study 31587982 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 100
Study 31036337 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment consisting of a slow infusion of 20 mg/kg ferric carboxymaltose, 40,000 U subcutaneous erythropoietin alpha, 1 mg subcutaneous vitamin B12, and 5 mg oral folic acid.
Number of subjects: 1006
Study 31036337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1006
Study 28719430 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hscTnT) assay
Number of subjects: 605
Study 28719430 — intervention group
Group type: COMPARATOR
Intervention: Contemporary cardiac troponin I (cTnI) assay
Number of subjects: 605
Study 28719430 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hscTnT) elevation
Number of subjects: 605
Study 27068432 — intervention group
Group type: EXPERIMENTAL
Intervention: Rutgeerts score (RS) assessment by endoscopists
Number of subjects: 39
Study 27068432 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic initiation based on RS ≥ i2
Number of subjects: 39
Study 27068432 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic initiation based on RS > i2
Number of subjects: 39
Study 25172229 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical petrolatum gel
Number of subjects: 50
Study 25172229 — intervention group
Group type: COMPARATOR
Intervention: Topical silver sulfadiazine with gauze dressings
Number of subjects: 50
Study 21455591 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential abdominoplasty
Number of subjects: 40
Study 21455591 — intervention group
Group type: COMPARATOR
Intervention: Augmentation mammoplasty with mastopexy
Number of subjects: 40
Study 19128802 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg oid) for 6 months
Number of subjects: 20
Study 19128802 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril (4 mg oid) for 6 months
Number of subjects: 20
Study 19128802 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of verapamil and trandolapril for additional 6 months
Number of subjects: 20
Study 19128802 — intervention group
Group type: COMPARATOR
Intervention: Control group (Trandolapril)
Number of subjects: 20
Study 19128802 — intervention group
Group type: COMPARATOR
Intervention: Control group (Verapamil)
Number of subjects: 20
Study 17337881 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic Positive Airway Pressure (APAP)
Number of subjects: 21
Study 17337881 — intervention group
Group type: COMPARATOR
Intervention: Manual Continuous Positive Airway Pressure (CPAP)
Number of subjects: 21
Study 15564360 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sleep deprivation
Number of subjects: 20
Study 15564360 — intervention group
Group type: COMPARATOR
Intervention: Undisturbed night sleep
Number of subjects: 20
Study 11167209 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of elemental iron a day for the first two months after childbirth
Number of subjects: 90
Study 11167209 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of elemental iron + 0.35 mg of folic acid a day for the first two months after childbirth
Number of subjects: 90
Study 11167209 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 90
Study 9010903 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation program combining one-on-one counseling with self-help materials and community-wide activities.
Number of subjects: 100
Study 9010903 — intervention group
Group type: COMPARATOR
Intervention: Control county (no specific intervention details provided).
Number of subjects: 100
Study 9010903 — intervention group
Group type: EXPERIMENTAL
Intervention: Attending church once a month or more (intervention group).
Number of subjects: 100
Study 9010903 — intervention group
Group type: COMPARATOR
Intervention: Control group (attending church once a month or more).
Number of subjects: 100
Study 9010903 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention county (general).
Number of subjects: 100
Study 9010903 — intervention group
Group type: COMPARATOR
Intervention: Control county (general).
Number of subjects: 100
Study 7889813 — intervention group
Group type: EXPERIMENTAL
Intervention: Take-home methadone doses following each therapy session (Study 1)
Number of subjects: 25
Study 7889813 — intervention group
Group type: EXPERIMENTAL
Intervention: Take-home methadone doses earned following each therapy session attended (Study 2)
Number of subjects: 25
Study 7889813 — intervention group
Group type: EXPERIMENTAL
Intervention: Take-home methadone doses earned following attendance to two consecutive sessions (Study 2)
Number of subjects: 25
Study 7889813 — intervention group
Group type: EXPERIMENTAL
Intervention: Take-home methadone doses (both studies)
Number of subjects: 25
Study 3608630 — intervention group
Group type: EXPERIMENTAL
Intervention: Single preoperative application of an antibiotic with a high biliary elimination rate (ceftriaxone or apalcillin)
Number of subjects: 326
Study 3608630 — intervention group
Group type: COMPARATOR
Intervention: Control group without prophylactic antibiotic application
Number of subjects: 326
Study 29112001 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone ISM 75 mg intramuscular injections every 4 weeks
Number of subjects: 70
Study 26801980 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone replacement schemes (three different patterns)
Number of subjects: 0
Study 26801980 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 24587337 — intervention group
Group type: EXPERIMENTAL
Intervention: HealthyDiet (wholegrain, fatty fish 3 times a week, bilberries 3 portions per day)
Number of subjects: 131
Study 24587337 — intervention group
Group type: EXPERIMENTAL
Intervention: WGED (wholegrain and low postprandial insulin response grain products)
Number of subjects: 131
Study 24587337 — intervention group
Group type: COMPARATOR
Intervention: Control (refined wheat breads as cereal products)
Number of subjects: 131
Study 22992702 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour rhLH pulses
Number of subjects: 19
Study 22992702 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour rhLH pulses
Number of subjects: 19
Study 22992702 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous rhLH infusion
Number of subjects: 19
Study 22992702 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 19
Study 20420766 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram treatment for 8 weeks
Number of subjects: 20
Study 17883958 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL YZH oral liquid, 3 times daily for 14 d
Number of subjects: 18
Study 15749498 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) plus low-dose aspirin (LDA)
Number of subjects: 50
Study 15749498 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) plus low-dose aspirin (LDA)
Number of subjects: 50
Study 12411644 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet activation markers (CD62p and CD63) after ischemic stroke
Number of subjects: 50
Study 12411644 — intervention group
Group type: EXPERIMENTAL
Intervention: CD62p expression
Number of subjects: 50
Study 12411644 — intervention group
Group type: EXPERIMENTAL
Intervention: CD63 expression
Number of subjects: 50
Study 12411644 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of platelet activation markers with inflammatory parameters
Number of subjects: 50
Study 7760409 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol resuscitation goals (CI > or = 4.5 L/min/m2, DO2I > or = 670 mL/min/m2, VO2I > or = 166 mL/min/m2)
Number of subjects: 125
Study 7760409 — intervention group
Group type: COMPARATOR
Intervention: Control resuscitation goals (normal vital signs, urine output, and central venous pressure)
Number of subjects: 125
Study 2244639 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo maintained for an additional 6 weeks
Number of subjects: 50
Study 2244639 — intervention group
Group type: COMPARATOR
Intervention: Placebo discontinued
Number of subjects: 50